

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Application Number	09/623,922
Filing Date	August 31, 2001
First Named Inventor	Papadopoulos, Vassilios
Group Art Unit	1647
Examiner Name	Dang, Ian

Sheet 1 of 3

Attorney Docket No: 1941.017US1

US PATENT DOCUMENTS

Examiner Initial *	USP Document Number	Publication Date	Name of Patentee or Applicant of cited Document	Filing Date If Appropriate
--------------------	---------------------	------------------	---	----------------------------

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Foreign Document No	Publication Date	Name of Patentee or Applicant of cited Document	T ²
	WO-2007103162A2	09/13/2007	PAPADOPOULOS, V. , et al.	
	WO-97018826A1	05/29/1997	Chang, C. C., et al.	

OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		MEDLINE, ABSTRACT 91083838, 1 pg	
		Application Serial No. 09/762594 (Atty Ref 1941.015US1) Final Office Action mailed 12-14-2004, 17	
		Application Serial No. 09/762594 (Atty Ref 1941.015US1) Non Final Office Action mailed 6-23-2004, 17 pgs	
		Application Serial No. 09-762594 (Atty Ref 1941.015US1) Notice of Allowance mailed 8-30-2005, 4 pgs	
		Application Serial No. 09/762594 (Atty Ref 1941.015US1) Response filed 9-23-2004 to Non Final Office Action mailed 6-23-04, 15 pgs	
		Application Serial No. 11/331,940 (Atty Ref 1941.015US2) Preliminary Amendment filed 1-13-06, 7 pgs	
		Application Serial No. 11/331,940 (Atty Ref 1941.015US2) Response to Restriction Requirement filed 9-12-07, 7 pgs	
		Application Serial No. 11/331,940 (Atty Ref 1941.015US3) Restriction Requirement mailed 6-12-07, 10 pgs	
		Australian Application No. 2004235618 Office Action dated 1-16-07, 3 pgs	
		Australian Application No. 2004203650 Non Final Office Action mailed 10-27-06, 8 pgs	
		Australian Application No. 2004203650 Response filed 6-7-07 to Non Final Office Action mailed 10-27-06, 11 pgs	
		Australian Application No. 3096899 Office Action Response mailed 7-22-04, 5 pgs	
		Canadian Application No. 2327329 Office Action dated 1-17-07, 4 pgs	
		Canadian Application No. 2327329 Office Action dated 11-24-05, 5 pgs	
		Canadian Application No. 2327329 Response dated 5-19-06 to Office Action dated 11-24-05, 16 pgs	
		Canadian Application No. 2339328 Office Action dated 2-5-07, 2 pgs	
		Canadian Application No. 2339328 Office Action dated 5-11-06, 6 pgs	
		Canadian Application No. 2339328 Office Action Response dated 8-1-07 to Office Action dated 5-17-06, 16 pgs	

EXAMINER

/Ian Dang/

DATE CONSIDERED

12/04/2007

Substitute Disclosure Statement Form (PTO-1449)

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /I.D./

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Application Number	09/623,922
Filing Date	August 31, 2001
First Named Inventor	Papadopoulos, Vassilios
Group Art Unit	1647
Examiner Name	Dang, Ian

Sheet 2 of 3

Attorney Docket No: 1941.017US1

OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		Canadian Application No. 2339328 Office Action Response dated 11-2-06 to Canadian Office Action mailed 5-17-06, 7 pgs	
		European Application No 99 912 635.2 Office Action dated 3-12-04, 3 pgs	
		European Application No. 06076592.2 Communication dated 10-5-06, 1 pg	
		European Application No. 99 943 703.1 Office Action dated 10-21-05, 6 pgs	
		European Application No. 99 943 703.1 Office Action dated 4-13-05, 3 pgs	
		European Application No. 99 943 703.1 Communication dated 11-28-05	
		European Application No. 99 943 703.1 Response dated 5-23-06 to 11-28-05 Office Action, 3 pgs	
		European Application Serial No. 0607659.2 Extended European Search Report and Communication dated 9-29-06.pdf, 9 pgs	
		European Application Serial No. 0607659.2 Office Action dated 11-15-06, 3 pgs	
		European Application Serial No. 0607659.2 Office Action dated 7-20-07, 3 pgs	
		European Application Serial No. 0607659.2 Response dated 1-4-07, 9 pgs	
		International Search Report in PCT/US99/05853, 6 pgs	
		International Search Report in PCT/US99/18507 (8-9-07), 9 pgs	
		BRANCH, A., "A Good Antisense Molecule is Hard to Find", <u>Trends Biochem Sci.</u> , 23(2), (Feb., 1998),45-50	
		CASALOTTI, S. O., et al., "Structure of the rat gene encoding the mitochondrial benzodiazepine receptor", <u>Gene</u> , 121(2), (Nov., 16, 1992),377-381	
		DON, J., et al., "Identification and characterization of the regulated pattern of expression of a novel mouse gene, meg1, during the meiotic cell cycle", <u>Cell Growth Differ.</u> , 3(8), (August 1992),495-505	
		DON, J., M. musculus mRNA megl, <u>Database EMBL [Online] AC X64455</u> , (02/21/1992),2 Pages	
		ELLIS, L. M., et al., "Down-regulation of vascular endothelial growth factor in a human colon carcinoma cell line transfected with an antisense expression vector specific for c-src", <u>The Journal of Biological Chemistry</u> , 273(2), (Jan. 9, 1998),1052-1057	
		GLENNEY, J. R., et al., "The sequence of human caveolin reveals identity with VIP21, a component of transport vesicles", <u>FEBS Lett.</u> , 314(1), (Dec. 7, 1992),45-8	
		LI, HUA, et al., "Identification, Localization, and Function in Steroidogenesis of PAP7: A Peripheral-Type Benzodiazepine Receptor- and PKA (RI?Ñ)-Associated Protein", <u>Molecular Endocrinology</u> 15(12), (2001),2211-2228	
		LU, C., et al., "Endogenous Interleukin 6 Can Function as an in Vivo Growth-stimulatory Factor for Advanced-Stage Human Melanoma Cells", <u>Clinical Cancer Research</u> , 2(8), (1996),1417-1425	

EXAMINER

/Ian Dang/

DATE CONSIDERED

12/04/2007

Substitute Disclosure Statement Form (PTO-1449)

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional) is: Applicant is to place a check mark here if English language translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /I.D./

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Application Number	09/623,922
Filing Date	August 31, 2001
First Named Inventor	Papadopoulos, Vassilios
Group Art Unit	1647
Examiner Name	Dang, Ian

Sheet 3 of 3

Attorney Docket No: 1941.017US1

OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		MARRA, M. , et al., mo98e12.rl Stratagene mouse testis (#937308) "Mus musculus cDNA clone", Database EMBL [Online] AC AA174581, (Dec. 31, 1996),2 Pages	
		PAWLIKOWSKI, M. , et al., "Inhibition of Cell Proliferation of Human Gliomas by Benzodiazepines in vitro", Acta Neurol Scand., 77(3), XP002114582,(Mar. 1988),231-233	
		RESNICOFF, M. , et al., "Inhibition of rat C6 glioblastoma tumor growth by expression of insulin-like growth factor I receptor antisense mRNA", Cancer Immunol. Immunother., 42(1), (1996),64-68	
		RUTKA, J. T., et al., "Effects of antisense glial fibrillary acidic protein complementary DNA on the growth, invasion, and adhesion of human astrocytoma cells", Cancer Res., 54(12), (June 15, 1994),3267-72	
		SAMBROOK, J. , et al., Molecular Cloning - a Laboratory Manual, 2d Edition, Cold Spring Laboratory Press,(1989),9.47-9.62	
		SHER, I , et al., "Mutations uncouple human fibroblast growth factor (FGF)-7 biological activity and receptor binding and support broad specificity in the secondary receptor binding site of FGFs", Journal of Biological Chemistry, 274(49), (December 3, 1999),35016-35022	
		WAKI, M. , et al., "Antisense src expression inhibits U937 human leukemia cell proliferation in conjunction with reduction of c-myc expression", Biochem Biophys Res Commun., 201(2), (June 15, 1994),1001-7	
		WELLS, J. A., "Additivity of Mutational Effects in Proteins", Biochemistry, 29(37), American Chemical Soc.,(Sep. 18, 1990),8509-8517	

EXAMINER

/Ian Dang/

DATE CONSIDERED

12/04/2007

Substitute Disclosure Statement Form (PTO-1449)

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional) 2 Applicant is to place a check mark here if English language Translation is attached

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /I.D./